{
  "CitationSubset": [
    "IM"
  ],
  "KeywordList": [],
  "GeneralNote": [],
  "OtherAbstract": [],
  "SpaceFlightMission": [],
  "OtherID": [],
  "InvestigatorList": [],
  "PMID": "3025154",
  "DateCompleted": {
    "Year": "1987",
    "Month": "02",
    "Day": "19"
  },
  "DateRevised": {
    "Year": "2020",
    "Month": "04",
    "Day": "03"
  },
  "Article": {
    "ArticleDate": [],
    "Language": [
      "eng"
    ],
    "ELocationID": [],
    "Journal": {
      "ISSN": "0305-7453",
      "JournalIssue": {
        "Volume": "18 Suppl B",
        "Issue": "Suppl B",
        "PubDate": {
          "Year": "1986",
          "Month": "Oct"
        }
      },
      "Title": "The Journal of antimicrobial chemotherapy",
      "ISOAbbreviation": "J Antimicrob Chemother"
    },
    "ArticleTitle": "The efficacy and tolerance of intranasal interferons: studies at the Common Cold Unit.",
    "Pagination": {
      "StartPage": "153",
      "EndPage": "156",
      "MedlinePgn": "153-6"
    },
    "Abstract": {
      "AbstractText": [
        "Intranasal sprays of interferons (IFNs) given one day before and for three days after virus challenge can protect human volunteers from infection with rhinoviruses, coronavirus, and influenza. Longer dosage of IFN gives rise to nasal symptoms and signs such as bloodstained nasal discharge. More effective IFNs and regimes are therefore needed. IFN beta is active but the degree to which it will irritate the nose is unknown. Combining IFNs with synthetic antiviral drugs can produce synergistic increases in antiviral activity. It is suggested that these increases may be exploited in future experiments."
      ]
    },
    "AuthorList": [
      {
        "Identifier": [],
        "AffiliationInfo": [],
        "LastName": "Tyrrell",
        "ForeName": "D A",
        "Initials": "DA"
      }
    ],
    "PublicationTypeList": [
      "Journal Article"
    ]
  },
  "MedlineJournalInfo": {
    "Country": "England",
    "MedlineTA": "J Antimicrob Chemother",
    "NlmUniqueID": "7513617",
    "ISSNLinking": "0305-7453"
  },
  "ChemicalList": [
    {
      "RegistryNumber": "0",
      "NameOfSubstance": "Interferon Type I"
    },
    {
      "RegistryNumber": "0",
      "NameOfSubstance": "Recombinant Proteins"
    }
  ],
  "MeshHeadingList": [
    {
      "QualifierName": [],
      "DescriptorName": "Administration, Intranasal"
    },
    {
      "QualifierName": [
        "therapy"
      ],
      "DescriptorName": "Common Cold"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Drug Tolerance"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Humans"
    },
    {
      "QualifierName": [
        "administration & dosage"
      ],
      "DescriptorName": "Interferon Type I"
    },
    {
      "QualifierName": [
        "therapy"
      ],
      "DescriptorName": "Picornaviridae Infections"
    },
    {
      "QualifierName": [
        "administration & dosage"
      ],
      "DescriptorName": "Recombinant Proteins"
    },
    {
      "QualifierName": [
        "drug effects"
      ],
      "DescriptorName": "Rhinovirus"
    }
  ]
}